GlassScriptPhysician profile
Nazanin Saedi
NPI 1710178173
$49,149.58
in general payments reported to CMS, 2019-2025
28 companies · $1,407 in 2025
The $1,407 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,300 · 2020: $1,601 · 2021: $15K · 2022: $7,780 · 2023: $6,290 · 2024: $16K · 2025: $1,407.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $16K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,500 · Food and Beverage: $3,502 · Education: $53.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $15,529.97 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,500.00 |
| Food and Beverage | $3,502.24 |
| Education | $53.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $21,040.11 | 2020-2022 | |
| Abbvie INC. | $19,884.56 | 2022-2025 | Botox, Rinvoq, Skyrizi |
| Galderma Laboratories, L.P. | $5,386.50 | 2019-2025 | Dysport, Aklief, Oracea |
| Janssen Biotech, INC. | $634.79 | 2022-2025 | Tremfya, Simponi Aria, Remicade |
| Hologic INC | $500.00 | 2019 | |
| Genzyme Corporation | $305.04 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $234.78 | 2022-2025 | Dupixent, Libtayo |
| Amgen INC. | $131.83 | 2022-2024 | Otezla |
| Endo Pharmaceuticals INC. | $108.95 | 2019 | |
| Sun Pharmaceutical Industries INC. | $103.92 | 2022-2025 | Ilumya |
| Ucb, INC. | $103.23 | 2022-2025 | Bimzelx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $95.30 | 2022-2025 | Spevigo |
| Lilly USA, LLC | $87.12 | 2022-2025 | Olumiant, Taltz, Ebglyss |
| Incyte Corporation | $86.39 | 2024-2025 | Opzelura |
| Leo Pharma INC. | $61.17 | 2024 | Adbry |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $50.39 | 2019-2025 | |
| Helsinn Therapeutics (U.S.), INC. | $43.89 | 2023 | Valchlor |
| Organon LLC | $43.03 | 2025 | Vtama |
| Almirall LLC | $39.00 | 2024-2025 | Klisyri |
| Springworks Therapeutics, INC. | $34.26 | 2025 | Gomekli |
| Paratek Pharmaceuticals, INC. | $33.98 | 2024 | Nuzyra |
| Botanix Sb INC | $28.36 | 2025 | Sofdra |
| Dermavant Sciences, INC. | $24.46 | 2024 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $21.24 | 2024 | Sotyktu |
| Blueprint Medicines Corporation | $20.35 | 2025 | Ayvakit |
| Arcutis Biotherapeutics, INC. | $18.29 | 2024 | Zoryve |
| Journey Medical Corporation | $15.39 | 2025 | |
| Verrica Pharmaceuticals INC. | $13.25 | 2023 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nazanin Saedi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.